"ARVO 2023: Life Biosciences and Iveric Bio showcase promising vision restoration data in nonhuman primates and clinical trials"

TL;DR
Life Biosciences presented preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) conference demonstrating the ability to restore visual function in nonhuman primates (NHP) after delivery of a novel gene therapy candidate using a partial epigenetic reprogramming approach. The therapy significantly restored visual function in an NHP model of non-arteritic anterior ischemic optic neuropathy (NAION), a disorder similar to a stroke of the eye that is characterized by painless yet sudden loss of vision. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity.
Topics:businesshealth#epigenetic-reprogramming#gene-therapy#health#life-biosciences#nonhuman-primates#visual-function
- Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates GlobeNewswire
- Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting Business Wire
- ARVO 2023: Life Biosciences presents groundbreaking data at ARVO demonstrating Restoration of Visual Function in Nonhuman Primates Ophthalmology Times
- ARVO LIVE: Analysis of vision loss from GATHER clinical program Ophthalmology Times
- ARVO LIVE: Lexitas modified National Eye Institute scale Ophthalmology Times
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on GlobeNewswire